The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen

Hum Vaccin. 2011 Feb;7(2):220-4. doi: 10.4161/hv.7.2.14003. Epub 2011 Feb 1.


Background: In China, rabies vaccine is only permitted to use under the Essen 5-dose regimen for the rabies post-exposure prophylaxis (PEP). However, Purified chick embryo cell vaccine made in India (Rabipur) has been approved in use under 2-1-1 immune program in 2010. Our objective is to confirm the immunogenicity and safety of PVRV manufactured in China (SPEEDA) under 2-1-1 program, compared with Rabipur and with the Essen 5-dose regimen.

Methods: A total of 112 subjects were divided into three groups: 50 subjects in test group A, 32 subjects in control group B and 30 subjects in control group C. "Zagreb" 2-1-1 program was chosen for group A and B using SPEEDA and Rabipur, "Essen" 5-dose regimen was adopted for group C using SPEEDA, thus to observe the general and local reactions within 72 h post vaccination. Serum samples were also collected at D0, D7, D14 and D45 to determine the rabies serum neutralizing antibody by rapid fluorescent focus inhibition test (RFFIT).

Results: All groups showed similar immunogenicity. The neutralizing antibody titers at D14 and D45 of all subjects showed more than 0.5 IU/ml. No moderate and severe adverse effects were observed, though mild adverse reactions may occur.

Conclusions: PVRV (SPEEDA), under 2-1-1 regimen, is equally safe and immunogenic as the PCECV (Rabipur) for post-exposure prophylaxis vaccination.

MeSH terms

  • Adult
  • Animals
  • Antibodies, Viral / blood
  • China
  • Chlorocebus aethiops
  • Female
  • Humans
  • Immunization Programs*
  • Male
  • Middle Aged
  • Rabies Vaccines / adverse effects
  • Rabies Vaccines / immunology*
  • Vaccination / adverse effects*
  • Vero Cells


  • Antibodies, Viral
  • Rabies Vaccines